| Identification | Back Directory | [Name]
DGY-06-116 | [CAS]
2556836-50-9 | [Synonyms]
DGY-06-116
5-Pyrimidinecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-[[2-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]- | [Molecular Formula]
C32H33ClN8O2 | [MDL Number]
MFCD32899273 | [MOL File]
2556836-50-9.mol | [Molecular Weight]
597.11 |
| Chemical Properties | Back Directory | [density ]
1.347±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (418.68 mM; Need ultrasonic) | [form ]
Solid | [pka]
10.42±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM[1]. | [in vivo]
DGY-06-116 (Compound 15a; 5 mg/kg for 3 times every 12 h via intraperitoneal injection) is able to inhibit SRC for an extended duration in adult C57B6 mice, likely due to its ability to covalently bind the target[1].
DGY-06-116 exhibits a short half-life and high exposure (T1/2=1.29 h, AUC=12 746.25 min·ng/mL) following i.p. administration (5 mg/kg) in B6 mice[1]. | Animal Model: | Adult C57B6 mice[1] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection; for 3 times every 12 h | | Result: | Led to inhibition of p-SRCY416 at 2 and 4 h postdosing, compared to the vehicle controls.
Demonstrated SRC binding and inhibition at both 2 and 4 h postdosing compared to the vehicle controls. |
| [storage]
Store at -20°C | [References]
[1] Guangyan Du, et al. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. J Med Chem. 2020 Feb 27;63(4):1624-1641. DOI:10.1021/acs.jmedchem.9b01502
[2] Deepak Gurbani, et al. Structure and Characterization of a Covalent Inhibitor of Src Kinase. Front Mol Biosci. 2020 May 19;7:81. DOI:10.3389/fmolb.2020.00081 |
|
|